Sf9 Cells: a Versatile Model System to Investigate the Pharmacological Properties of G Protein-coupled Receptors
Overview
Authors
Affiliations
The Sf9 cell/baculovirus expression system is widely used for high-level protein expression, often with the purpose of purification. However, proteins may also be functionally expressed in the defined Sf9 cell environment. According to the literature, the pharmacology of G-protein-coupled receptors (GPCRs) functionally reconstituted in Sf9 cells is similar to the receptor properties in mammalian cells. Sf9 cells express both recombinant GPCRs and G-proteins at much higher levels than mammalian cells. Sf9 cells can be grown in suspension culture, providing an inexpensive way of obtaining large protein amounts. Co-infection with various baculoviruses allows free combination of GPCRs with different G-proteins. The absence of constitutively active receptors in Sf9 cells provides an excellent signal-to background ratio in functional assays, allowing the detection of agonist-independent receptor activity and of small ligand-induced signals including partial agonistic and inverse agonistic effects. Insect cell Gα(i)-like proteins mostly do not couple productively to mammalian GPCRs. Thus, unlike in mammalian cells, Sf9 cells do not require pertussis toxin treatment to obtain a Gα(i)-free environment. Co-expression of GPCRs with Gα(i1), Gα(i2), Gα(i3) or Gα(o) in Sf9 cells allows the generation of a selectivity profile for these Gα(i/o)-isoforms. Additionally, GPCR-G-protein combinations can be compared with defined 1:1 stoichiometry by expressing GPCR-Gα fusion proteins. Sf9 cells can also be employed for ligand screening in medicinal chemistry programs, using radioligand binding assays or functional assays, like the steady-state GTPase- or [(35)S]GTPγS binding assay. This review shows that Sf9 cells are a versatile model system to investigate the pharmacological properties of GPCRs.
Prabhala S, Marshall B, Galiardi J, Fan Y, Creamer E, Wood D J Chromatogr A. 2024; 1736:465430.
PMID: 39405639 PMC: 11533640. DOI: 10.1016/j.chroma.2024.465430.
Claff T, Mahardhika A, Vaassen V, Schlegel J, Vielmuth C, Weisse R ACS Pharmacol Transl Sci. 2024; 7(5):1415-1425.
PMID: 38751633 PMC: 11091970. DOI: 10.1021/acsptsci.4c00051.
Agonist-selective activation of individual G-proteins by muscarinic receptors.
Nelic D, Chetverikov N, Hochmalova M, Diaz C, Dolezal V, Boulos J Sci Rep. 2024; 14(1):9652.
PMID: 38671143 PMC: 11053168. DOI: 10.1038/s41598-024-60259-4.
Animal Cell Lines as Expression Platforms in Viral Vaccine Production: A Post Covid-19 Perspective.
Demirden S, Kimiz-Gebologlu I, Oncel S ACS Omega. 2024; 9(15):16904-16926.
PMID: 38645343 PMC: 11025085. DOI: 10.1021/acsomega.3c10484.
Gleixner J, Kopanchuk S, Gratz L, Tahk M, Laasfeld T, Veiksina S ACS Pharmacol Transl Sci. 2024; 7(4):1142-1168.
PMID: 38633582 PMC: 11019746. DOI: 10.1021/acsptsci.4c00013.